RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

This study is testing an experimental drug called RRx-001 to reduce oral mucositis — painful sores in the mouth and throat — that commonly develops during radiation and chemotherapy treatment for head and neck cancer. **You may be eligible if...** - You have confirmed squamous cell carcinoma of the oral cavity or oropharynx (mouth or throat cancer) - You are planned to receive standard intensity-modulated radiation therapy (IMRT) with daily fraction doses of 2.0 Gy or higher - You may also be receiving concurrent chemotherapy - You are eligible for concurrent chemoradiation treatment **You may NOT be eligible if...** - Your cancer is at a stage or location that does not require radiation doses meeting study criteria - You have serious medical conditions that make participation unsafe - You have had prior radiation to the head or neck - You cannot swallow oral medications or receive intravenous infusions Talk to your doctor to see if this trial is right for you.